Molecular Cancer · 2014 · 138 citations · 26 references
MedicineCancer BiologyOncologyMetastasisMolecular OncologyNeoplasiaCancer ProgressionLung CancerLung MetastasisMalignant NeoplasmsNoncoding Rna In CancerEpithelial-mesenchymal Transition In CancerEpithelial-mesenchymal Transition MarkersLoss-of-function ModelsMicrorna Function In CancerMicrorna Regulation In CancerMicrorna Regulation Of EmtMicrorna-mediated ResistanceRegulators
BACKGROUND: MicroRNAs (miRNAs) have been identified as important posttranscriptional regulators involved in various biological and pathological processes of cells, but their association with tumor chemoresistance has not been fully understood. METHODS: We detected miR-27a expression in two lung adenocarcinoma cell lines, A549 and A549/CDDP, and then investigated the effects of miR-27a on the metastasis and the chemosensitivity of cancer cells, using both gain- and loss-of-function studies. The correlation between miR-27a level and chemoresistance was further investigated in clinical lung adenocarcinoma specimens. RESULTS: miR-27a was significantly up-regulated in cisplatin-resistant lung adenocarcinoma A549/CDDP cells compared with parental A549 cells. miR-27a regulates epithelial-mesenchymal transition (EMT) and cisplatin resistance in vitro and modulates response of lung adenocarcinoma cells to cisplatin in vivo. Further studies identified Raf Kinase Inhibitory Protein (RKIP) as a direct and functional target of miR-27a. Small interfering RNA-mediated RKIP knockdown revealed similar effects as that of ectopic miR-27a expression, while overexpression of RKIP attenuated the function of miR-27a in lung adenocarcinoma cells. Increased miR-27a expression was also detected in tumor tissues sampled from lung adenocarcinoma patients treated with cisplatin-based chemotherapy and was proved to be correlated with low expression of RKIP, decreased sensitivity to cisplatin, and poor prognosis. CONCLUSION: Our results suggest that up-regulation of miR-27a could suppress RKIP expression and in turn contribute to chemoresistance of lung adenocarcinoma cells to cisplatin.
26
Ahmedin Jemal, Rebecca L. Siegel, Jiaquan Xu et al. · CA A Cancer Journal for Clinicians · 2010 · 12.6K citations · Full text
Ahmedin Jemal, Michael J. Thun, Lynn A. G. Ries et al. · JNCI Journal of the National Cancer Institute · 2008 · 955 citations · Full text
Susanne U. Mertens‐Talcott, Sudhakar Chintharlapalli, Xiangrong Li et al. · Cancer Research · 2007 · 466 citations · Full text